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ABSTRACT
Introduction: Viral hepatitis is a group of diseases that present high hepatotropism 
and are related to liver dysfunctions, having either an acute or a chronic course. 
Their worldwide epidemiology is diverse, with several endemic places, such as South 
America. The objective of this study was to analyze the epidemiology of viral hepatitis 
in Brazil, in order to better understand its pattern of distribution and evolution.
Method: A temporal aggregation study was conducted using the Viral Hepatitis 
Database of the Brazilian Ministry of Health. The serological markers used were HBsAg 
and anti-HCV for hepatitis B and C, respectively. Mortality data were collected from 
the Mortality Information System for deaths attributed to viral hepatitis. The period 
analyzed was from 2007 to 2016/17.
Results: The incidence was 7.88 (95% CI, 7.30-8.45) for hepatitis B and 11.9 
(95% CI, 11.15-12.65) for hepatitis C. Mortality attributed to viral hepatitis was 1.61 
(95% CI, 1.35-1.87) deaths per 100,000 people. An analysis of municipal distribution 
data showed several endemic areas. The Brazilian regions most affected by hepatitis 
B virus were the northern and southern borders, Santa Catarina coast and Espírito 
Santo state, while hepatitis C virus was mostly present in metropolitan areas such 
as Porto Alegre and São Paulo.
Conclusions: Viral hepatitis has a diverse geographic distribution in the Brazilian 
territory, with highly endemic areas. The distribution differs between hepatitis B and 
hepatitis C viruses.
Keywords: Hepatitis; epidemiology; mortality; Brazil
Viral hepatitis is a group of diseases of universal distribution caused by 
different etiological agents1-3. They share clinical and laboratory similarities, 
especially hepatotropism, but with differences in epidemiology and progressive 
course1,2,4.
Hepatitis B virus (HBV) infection affects around two billion people worldwide, 
of which 240-280 million are diagnosed with chronic hepatitis B. Among 
the consequences of its progression are the development of cirrhosis and 
hepatocellular carcinoma, which are serious hepatic lesions of great clinical 
concern3,5-8.
HBV transmission occurs by contact with infected blood and body fluids 
through reused or unsterilized medical/dental devices, tattooing and piercing, 
and illicit injecting drugs (when sharing needles and syringes). In addition, 
transmission can occur when personal objects, such as toothbrushes and 
nail clippers, are shared in a family context8-11.
There are several serologic markers available for HBV. HBsAg was 
the first marker, discovered in 1965, consisting of a viral surface antigen 
present in the acute phase of the disease and in its chronification. Negativity 
of this marker and appearance of its antibody – anti-HBs – are associated 
with non‑chronification of the virus. Other markers used are anti‑HBc IgM 
(early immunity) and IgG (immunological scar), HBeAg and anti-HBe. Viral load 
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testing using polymerase chain reaction (PCR) is a 
commonly used method2-4.
Hepatitis C virus (HCV) infection affects 
approximately 150 million people worldwide. More 
than 350,000 cases per year progress to death due 
to the same serious liver diseases that occur with 
HBV7,12,13. Risk groups include those who received 
blood transfusions and/or blood products prior to 
1992, intravenous drug users, people with tattoos and 
piercings, HIV carriers, transplanted, hemodialyzed 
or hemophiliac patients, the incarcerated population 
and those who are sexually promiscuous2,10,14,15.
The serological marker for HCV screening is total 
anti-HCV. This enzymatic marker commonly used 
in enzyme-linked immunosorbent assay (ELISA) 
is associated with false-positive results; therefore, 
when a result is positive, viral load testing with PCR 
must be performed to confirm the infection. However, 
due to financial limitations, anti‑HCV is the marker of 
choice when screening patients for blood donation 
and organ transplantation16.
The control of endemic-epidemic diseases 
remains a major challenge in the Brazilian setting. 
Socioeconomic heterogeneity, irregular distribution 
of health services, and unequal incorporation of 
advanced technology for diagnosis and treatment of 
diseases are important issues to be considered in 
the evaluation of the endemic-epidemic process of 
viral hepatitis17. Therefore, epidemiological studies 
are essential for creating public strategies to combat 
and prevent the diseases affecting the population, 
especially if they are concentrated in a given region18.
Thus, this study aimed to analyze Brazilian data 
on the epidemiology of HBV and HCV infections in 
different regions, based on data from 2007 to 2016/17, 
in addition to correlating incidence with mortality 
rates. Individual studies addressing each region could 
provide more information about regional settings 
and allow for specific actions implemented locally.
METHOD
Design, Population, Sample
A temporal aggregation study was retrospectively 
conducted using an exploratory and quantitative 
documentary approach. Data were obtained from the 
Brazilian Ministry of Health Notification Information 
System (SINAN) and Mortality Information System 
(SIM), both available from the DATASUS Health 
Information System19. Demographic data for each 
year, age group and sex were obtained through the 
Brazilian Institute of Geography and Statistics (IBGE)20.
The variables observed were the reactive serological 
results for HBsAg and total anti-HCV in the period of 
2007 to 2017. Mortality consisted of the total number 
of confirmed deaths due to viral hepatitis (ICD 10: 
B15-B19), both in its acute and chronic forms, for 
the period of 2007 to 2016. The data collected 
were analyzed as divided by the 27 Brazilian states 
and the Federal District – a division recommended 
by IBGE. For a comprehensive analysis, the five 
administrative regions of Brazil – namely South, 
Southeast, Midwest, North and Northeast – were also 
studied. The sample was divided into years of death, 
sex and age (0‑19, 20‑39, 40‑59, 60‑79, ≥80 years). 
For mortality and incidence rates, data were presented 
in calculations for every 100,000 women or men.
The municipal distribution graphs of serum incidence 
of HBsAg and anti-HCV were based on SINAN data 
for each municipality and on the correlation with 
municipal areas (called “polygons”) available from 
IBGE. Tableau software, version 10.5, was used to 
create the graphs.
SIM and SINAN consist of Brazilian Ministry of 
Health open access databases. Patient data are 
unidentified, and their purpose is to provide a national 
epidemiological profile. Therefore, these are official 
government data.
Statistical Analysis
The data were treated statistically and analyzed 
quantitatively in Microsoft Excel 2010 (Microsoft 
Corp., USA) and Gran Graphic Prisma, version 6. 
For different years, statistical comparisons were 
performed using Student’s t-test for parametric 
variables and Mann-Whitney U test for non-parametric 
variables. The data were also treated descriptively. 
The results are shown in graphs and tables for better 
interpretation. Significant values were considered 
when p≤0.05.
RESULTS
In the study period, 154,542 serological tests 
were positive for HBV and 233,449 for HCV, while 
28,293 deaths were attributed to viral hepatitis in 
Brazil. When the populations were correlated, the rates 
were 7.88 (95% CI, 7.30-8.45) for HBV, 11.9 (95% CI, 
11.15-12.65) for HCV and 1.61 (95% CI, 1.35-1.87) 
deaths per 100,000 people (Table 1).
In the male population, the age group most affected 
by HBV was 40-59 years (42%), while in the female 
population it was 20-39 years (53%). For HCV, the 
most affected age group was 40‑59 years (54%). 
The peak mortality was 40-59 years of age (43%) 
due to liver dysfunctions.
The evolution pattern of these infections from 
2007 to 2017 was analyzed (Figure 1). There was 
a 64% decrease (p = 0.001) in the serum incidence 
of HBsAg in both male and female populations of 
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Table 1: Serum incidence of HBsAg and anti-HCV and mortality rate attributed to viral hepatitis per federal unit.
Federal units Hepatitis B virus Hepatitis C virus MortalityIncidence 95% CI Incidence 95% CI Incidence 95% CI
Rio Grande do Sul 11.06 11.68-14.13 67.37 63.08-71.66 3.81 3.19-4.43
Santa Catarina 23.94 22.01-25.87 17.13 15.97-18.28 1.53 1.27-1.78
Paraná 17.85 15.96-19.75 11.39 9.8-12.98 1.52 1.27-1.77
São Paulo 7.85 7.32-8.38 17.43 16.32-18.54 2.37 1.98-2.76
Rio de Janeiro 4.01 3.29-4.74 9.58 7.58-11.57 2.41 2.02-2.81
Minas Gerais 4.2 3.74-4.65 5.75 4.69-6.81 0.9 0.75-1.05
Espírito Santo 12.77 11.69-13.86 5.59 4.77-6.42 1.35 1.1-1.6
Mato Grosso do Sul 7.25 5.75-8.75 8.61 7.14-10.09 1.44 1.16-1.73
Mato Grosso 20.22 18.2-22.24 6.65 5.58-7.73 1.19 0.96-1.42
Goiás 6.1 5.49-6.71 3.8 3.04-4.56 1.18 0.98-1.38
Distrito Federal 6.96 5.11-8.82 8.9 6.95-10.85 1.01 0.81-1.22
Acre 86.22 69.17-103.27 29.33 19.29-39.27 1.55 1.29-1.81
Rondônia 36.83 24.45-49.20 8.79 3.75-13.83 2.08 1.69-2.48
Amazonas 17.91 13.23-22.59 7.11 4.51-9.72 2.31 1.88-2.73
Roraima 21.3 18.45-24.15 3.94 2.99-4.9 1.36 0.9-1.81
Pará 2.92 2.42-3.41 2.07 1.55-2.59 0.75 0.6-0.9
Amapá 4.86 3.92-5.81 4.26 3.61-4.9 0.59 0.43-0.74
Tocantins 8.04 7.23-8.84 3.2 2.83-3.57 0.84 0.63-1.05
Maranhão 3.17 2.58-3.76 2.38 1.87-2.88 0.94 0.78-1.1
Piauí 1.42 1.14-1.7 1.26 0.82-1.71 0.67 0.54-0.81
Ceará 2 1.87-2.13 2.31 1.79-2.82 0.47 0.38-0.57
Rio Grande do Norte 1.54 1.3-1.78 2.45 2.12-2.78 0.7 0.56-0.83
Paraíba 2.72 2-3.45 2.19 1.64-2.74 0.61 0.48-0.74
Pernambuco 2.21 1.67-2.75 2.75 2.05-3.44 1.07 0.88-1.27
Alagoas 3.73 2.98-4.48 2.1 1.66-2.54 0.73 0.59-0.88
Sergipe 5.94 5.42-6.46 3.19 2.8-3.57 0.75 0.55-0.94
Bahia 3.32 2.77-3.88 3.64 3.04-4.24 0.77 0.63-0.9
Figure 1: Demonstrating serum incidence of HBsAg and Anti-HCV and mortality rate by age group during 2007-17.
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up to 20 years of age. Serum incidence of anti-HCV 
increased by 47% (p = 0.0001) and by 52% (p = 0.03) 
in the populations aged 60-79 years and above 
80 years, respectively. Mortality was analyzed up 
to 2016 and showed a 70% reduction (p = 0.01) in 
the population aged up to 20 years.
A geographical analysis, demonstrated visually 
in Figure 2, illustrates the pattern of HBV endemic 
regions. The most affected areas were the northern 
border (Acre, Amazonas, Rondônia and Mato Grosso 
states) and the southern border (Paraná, Santa 
Catarina and Rio Grande do Sul states). However, 
it is worth mentioning that there were other endemic 
spots in Brazil, such as Santa Catarina northern 
coast and Espírito Santo state.
When the same analysis was performed for 
HCV, the pattern was different from HBV (Figure 3). 
The most affected regions were metropolitan areas 
such as Porto Alegre, Santa Catarina and Paraná 
coasts, São Paulo and Mato Grosso do Sul states. 
The border shared with Bolivia and Peru was also 
highly endemic.
DISCUSSION
Viral hepatitis is a serious public health problem 
accounting for 1.4 million deaths worldwide. In Brazil, 
there is a large regional variation in the prevalence 
of each of the etiological agents, which cross state 
borders. These differences are related to regional 
economic and population characteristics. Viral 
hepatitis affects a great number of individuals in 
the country, involving complications of its acute and 
chronic forms3,4,21.
The economic impact associated with hepatitis is 
relevant because, in endemic areas, the development 
of hepatocellular carcinoma and cirrhosis occurs 
in the young population, leading to decades of 
productive lives compromised. In the more advanced 
stages of disease progression, the costs are very 
high due to the consumption of health resources, 
such as hospitalizations, medical consultations, 
medications, tests and, in some cases, the need for 
liver transplantation15.
Transmission of HBV and HCV is mainly related 
to blood contamination due to injecting drug use, 
formerly due to contaminated blood transfusion. 
Sexual intercourse is still somewhat controversial 
in HCV transmission, with conflicting data in the 
literature, while in HBV transmission its role has 
already been proven6,22-24.
Even when the virus is transmitted, many patients 
may not become chronically infected, as factors 
such as contact age, virus type, viral load and 
method of transmission are important variables for 
chronification. The acquisition of HBV infection during 
childhood, mainly from maternal source, presents 
high chronification rates ranging from 90 to 95%. 
However, when infection is acquired in adulthood, 
chronification affects only 5% of the individuals8,15. 
Conversely, HCV infection has high chronification 
rates, close to 95%.
A geographical analysis of Map 1, which reveals 
the pattern of HBV endemic regions in the country, 
indicates the northern and southern borders as the 
most affected areas. The involvement of border 
areas could be explained by the fact that they are 
less developed and have difficulties in consolidating 
control measures, such as vaccination and prenatal 
care6,23,25. In the northern border, Acre, Amazonas, 
Rondônia and Mato Grosso states have high birth 
rates; thus, the virus can be transmitted from mother to 
child, which has been frequently described in endemic 
areas such as East Asia and Sub-Saharan Africa25.
Figure 2: Municipal geographical distribution of serum 
HBsAg incidence between 2007-17.
Figure 3: Municipal geographical distribution of serum 
anti-HCV incidence between 2007-17.
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There are several studies showing that the 
presence of family members infected with HBV is 
associated with a higher frequency of other infected 
members. The present results can be used to explain 
why there is a high prevalence of infected individuals 
in southern and northern areas, consistent with 
the hypothesis of virus transmission in the family 
environment9,26,27.
The prevalence of HCV, as seen in Map 2, was 
higher in metropolitan areas such as Porto Alegre, 
Santa Catarina and Paraná coasts, São Paulo 
and Mato Grosso do Sul states. Drug injection is 
the most important risk factor for the acquisition of 
HCV infection in large urban centers, especially in 
young individuals. In addition, the high prevalence 
in satellite cities may be explained by the large influx 
of migrants15,24,28,29.
In the study period, there was a decrease in 
mortality due to viral hepatitis and in the number 
of HBV infections in the 0-19 years age group. 
Some possible explanations for these results are 
governmental measures such as HBsAg screening 
for pregnant women and incorporation of hepatitis 
A and B vaccines into the immunization schedule, 
now available to all people regardless of age. 
However, the increase in HCV infection found in 
older age groups may be due to a greater demand 
for serological tests30.
The data analyzed in the present study were 
selected from official Ministry of Health databases. 
All positive HBsAg and anti-HCV results are required 
to be submitted to the Brazilian government. Thus, 
these databases allow an analysis of the health 
panorama in Brazil.
CONCLUSION
Viral hepatitis in the Brazilian context has high 
heterogeneity, with several endemic areas for both 
HBV and HCV. These patterns are associated with 
virus characteristics and local peculiarities. There 
was a decrease in HBV infection and mortality 
rates in the young population, possibly due to the 
consolidation of government programs. However, 
the current situation is not encouraging because 
chronification is associated with a number of morbid 
conditions and a high cost to society.
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